glp1ledger

Trulicity (Dulaglutide): What the 2026 Label Approves, the Heart Trial Behind It, Side-Effect Rates and the Savings Card

Trulicity is Eli Lilly's once-weekly dulaglutide pen for type 2 diabetes in adults and children from age 10, with a heart-risk indication that — unlike most of its class — also covers people without established heart disease. The label's indications, the REWIND trial, its side-effect table, the four pens and the savings card's terms, read from the documents.

Ronald R · Edited by Caroline S · Published 2026-10-06 · Updated 2026-11-18

Illustration: A plain white unbranded box on a light wooden surface in soft natural light.
Illustration

Trulicity is the once-weekly dulaglutide pen Eli Lilly has sold for type 2 diabetes since 2014. Its current label approves it for blood-sugar control in adults and in children from age 10, and for reducing heart attacks, strokes and cardiovascular deaths — and, unusually for its class, that heart indication covers people who have risk factors but no established heart disease. It is not approved for weight loss. This page reads the label, its heart trial, its side-effect table and Lilly's savings terms.

Sources were first read on 6 October 2026: the Trulicity prescribing information (Eli Lilly, DailyMed, effective 16 June 2026) and the Trulicity Savings Card terms on trulicity.com. The label and FDA's action record were re-read on 18 November 2026 (below); the label in force is unchanged. This page reports what those documents say; it gives no dosing guidance and no view on whether Trulicity suits anyone.

What the label approves

Indication Who Not covered
Lowering blood sugar, next to diet and exercise Type 2 diabetes from age 10 upward, adults included Weight loss; type 1 diabetes
Reducing major adverse cardiovascular events Adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors Children; people without diabetes

The second row is the detail most summaries miss. The heart indications of Ozempic and Victoza name adults with established cardiovascular disease; Trulicity's wording also reaches the larger group who have only risk factors, because that is who its outcome trial enrolled. LEADER, the outcomes trial behind Victoza's heart indication, is summarised on the Victoza page.

REWIND, the trial behind the heart indication

REWIND randomised 9,901 adults with type 2 diabetes to Trulicity 1.5 mg or placebo, on top of usual care, and followed them for a median 5.4 years. Its population was older and earlier in risk than most outcome trials: mean age 66, median HbA1c 7.2%, and 62.8% without established cardiovascular disease.

Outcome (first occurrence) Trulicity (n=4,949) Placebo (n=4,952) Hazard ratio (95% CI)
Cardiovascular death, non-fatal heart attack or non-fatal stroke 594 (12.0%) 663 (13.4%) 0.88 (0.79–0.99)
Cardiovascular death 317 (6.4%) 346 (7.0%) 0.91 (0.78–1.06)

From the label's section 14.5; the component results are listed "for supportive purposes" and the label states no statistical significance should be inferred from them.

Read as absolute numbers, the composite outcome happened to 1.4 more people per 100 on placebo than on Trulicity over about five years — roughly one event avoided for every 71 people treated for that period (glp1ledger arithmetic from the label's percentages, a crude ratio that ignores the timing of events). The upper end of the confidence interval, 0.99, sits just under 1.

The side-effect table

The label's adverse-reaction table pools placebo-controlled trials of 1,670 adults on Trulicity, with a mean exposure of 23.8 weeks. It reports only the two original strengths.

Reaction Placebo 0.75 mg 1.5 mg
Nausea 5.3% 12.4% 21.1%
Vomiting 2.3% 6.0% 12.7%
Diarrhoea 6.7% 8.9% 12.6%
Abdominal pain 4.9% 6.5% 9.4%
Decreased appetite 1.6% 4.9% 8.6%
Indigestion (dyspepsia) 2.3% 4.1% 5.8%
Fatigue 2.6% 4.2% 5.6%

Counted as one group, stomach and bowel complaints touched roughly two in five people on the 1.5 mg pen (41%), one in three on 0.75 mg (32%) and one in five on placebo (21%). They made 3.5% of the 1.5 mg group give up the drug, against 0.2% of the placebo group. About half were rated mild by the investigators; the share rated severe was 7% at 0.75 mg and 11% at 1.5 mg. How these rates compare across the class is on GLP-1 side effects and the GLP-1 with the fewest side effects.

Trulicity's warning list follows the pattern every GLP-1 label shares. At the top sits the boxed warning about thyroid C-cell tumours in rats and mice, which bars dulaglutide for anyone with medullary thyroid carcinoma or MEN 2 in their own or their family's history. Below it come pancreatitis, low blood sugar when paired with insulin or a sulfonylurea, serious allergy, kidney injury after dehydration, severe stomach and bowel reactions, worsening of existing diabetic eye disease, gallbladder problems, and the aspiration risk under anaesthesia.

The stomach record, and Trulicity as the yardstick

Section 5.6 of the label gives a figure most summaries leave out: severe gastrointestinal reactions were reported by 2.2% on 0.75 mg and 4.3% on 1.5 mg, against 1.4% on placebo, and Trulicity "is not recommended in patients with severe gastroparesis". Those are Trulicity's own trial pools; other GLP-1 labels report the same measure from different trials, so the percentages are not a head-to-head ranking.

The better comparison comes from outside the label. Because dulaglutide is the oldest weekly GLP-1 still widely used, researchers use it as the yardstick. A 2026 Annals of Internal Medicine cohort of adults with type 2 diabetes (Crisafulli and colleagues, PMID 41183330) matched 65,238 people starting semaglutide and 20,893 starting tirzepatide against people starting Trulicity, and measured a composite of pancreatitis, gallbladder disease, bowel obstruction, gastroparesis and severe constipation. The hazard ratio was 0.96 (95% CI 0.87–1.06) for semaglutide against dulaglutide and 0.96 (0.77–1.20) for tirzepatide against dulaglutide: no measurable difference. FDA's adverse event database, read on 18 November 2026, files 2,003 of its 89,369 dulaglutide reports under "impaired gastric emptying" (2.2%); report shares follow publicity and litigation more than risk. The full record on the question is on Ozempic and stomach paralysis.

The four pens

Every Trulicity pen is used once and thrown away. Each delivers 0.5 mL, and the four strengths are 0.75 mg, 1.5 mg, 3 mg and 4.5 mg; Lilly makes no vial and no reusable pen for dulaglutide. Pens live in the fridge at 2–8°C in their carton, away from light. The label lets a pen spend up to 14 days in total out of the fridge, provided it stays at or below 30°C (86°F), and a pen that has frozen is discarded. How storage rules differ between GLP-1 pens is on GLP-1 pen storage. The doses themselves are a prescriber's decision and are not set out here.

Children aged 10 and older

The paediatric approval rests on one trial (NCT02963766): 154 young people aged 10 to 17 (mean 14.5 years, 71% female, mean weight 90.5 kg) with type 2 diabetes, randomised to Trulicity or placebo for 26 weeks with a 26-week open-label extension. Trulicity was superior to placebo on HbA1c at week 26. The cardiovascular indication does not extend to children.

The savings card

Lilly's Trulicity Savings Card is a copay card for people whose commercial plan covers Trulicity. Its terms, read on trulicity.com:

Term Trulicity card
Patient pays as little as $25 for a 1-, 2- or 3-month fill
A "month" 28 days and up to 4 pens
Monthly cap $150 per 1-month fill · $300 per 2 · $450 per 3
Yearly cap $1,950 per calendar year
Fill limit 13 fills a year
Ends 31 December 2026
Excluded Medicare, Medicaid and other government beneficiaries; under-18s; plans using an alternate funding programme

The arithmetic matches Lilly's Mounjaro card: $25 is reached only where the plan's copay is $175 or less for a 28-day fill; above that the card is a flat $150 discount. The Mounjaro terms are on the Mounjaro savings card. Lilly's list-price page for Trulicity refused automated access when this page was written, so no list price is quoted here.

Trulicity in the class

Dulaglutide's once-a-week dosing comes from its structure: two copies of a GLP-1-like peptide joined to a fragment of an antibody, which keeps the molecule in the blood far longer than natural GLP-1. It reached the market in 2014, years before semaglutide or tirzepatide, and Lilly never developed a weight-loss brand of it.

FDA's record for Trulicity (biologics licence BLA 125469, read through openFDA on 18 November 2026) lists 22 actions: the original approval on 18 September 2014, seven efficacy supplements between January 2017 and November 2022, and labelling changes, the latest approved on 12 March 2026. DailyMed shows the current label as SPL version 62, effective 16 June 2026 and published 10 August 2026. The one head-to-head trial against Ozempic is set out on Trulicity vs Ozempic, and how it sits among every approved GLP-1 on which drugs are GLP-1s. The library entry on the molecule itself is PeptideLexicon's dulaglutide.

Sources

Eli Lilly, TRULICITY (dulaglutide) injection prescribing information, DailyMed setid 463050bd-2b1c-40f5-b3c3-0a04bb433309 (SPL effective 2026-06-16), sections 1, 3, 5, 6.1, 14.5, 14.6 and 16.2, read 6 October 2026, version 62 re-checked 18 November 2026 · FDA Drugs@FDA record for BLA 125469 via openFDA, read 18 November 2026 · Crisafulli S et al., Ann Intern Med 2026;179(1):1-11, PMID 41183330 · FDA Adverse Event Reporting System via openFDA (updated 2026-10-28), read 18 November 2026 · Eli Lilly, Trulicity Savings Card terms and conditions, trulicity.com/savings-resources, read 6 October 2026 · pricinginfo.lilly.com/trulicity returned HTTP 403 to automated requests on 6 October 2026 and is not quoted.

Frequently asked questions

What is Trulicity used for?

Two things, both in type 2 diabetes. Lilly's label lets dulaglutide be used to bring blood sugar down, next to diet and exercise, from age 10 upward; and, in adults only, to cut the chance of a heart attack, a stroke or a cardiovascular death, where the person already has heart disease or carries several of its risk factors. Weight loss and type 1 diabetes are outside the label.

What are the most common side effects of Trulicity?

In the label's pooled placebo-controlled trials, the most common were nausea (21.1% on 1.5 mg vs 5.3% on placebo), vomiting (12.7% vs 2.3%), diarrhoea (12.6% vs 6.7%), abdominal pain (9.4% vs 4.9%), decreased appetite (8.6% vs 1.6%), indigestion (5.8% vs 2.3%) and fatigue (5.6% vs 2.6%). Gastrointestinal reactions led 3.5% of people on 1.5 mg to stop, against 0.2% on placebo.

Is Trulicity the same as Ozempic?

No. Trulicity is dulaglutide, made by Eli Lilly; Ozempic is semaglutide, made by Novo Nordisk. Both are once-weekly GLP-1 receptor agonist injections for type 2 diabetes with a cardiovascular indication, but they are different molecules with different trials, pens and labels. The trial that compared them directly is covered on this site's Trulicity vs Ozempic page.

Is there a Trulicity coupon or savings card?

Lilly's Trulicity Savings Card offers a $25 fill for people with commercial insurance that covers Trulicity. Per its terms, it pays at most $150 per 28-day fill and $1,950 per calendar year, can be used for up to 13 fills a year, excludes Medicare, Medicaid and other government beneficiaries, requires the holder to be 18 or older, and ends on 31 December 2026.

Does Trulicity cause stomach paralysis?

The Trulicity label does not list gastroparesis as a side effect; it says the drug is not recommended for people who already have severe gastroparesis. Severe gastrointestinal reactions were reported by 2.2% on 0.75 mg and 4.3% on 1.5 mg against 1.4% on placebo. In a 2026 Annals of Internal Medicine cohort that used Trulicity as the comparison drug, semaglutide and tirzepatide showed no difference from it on a composite of serious gut events that included gastroparesis.

Can children take Trulicity?

The label approves Trulicity for glycaemic control in paediatric patients 10 years and older with type 2 diabetes. The approval rests on a 26-week placebo-controlled trial (NCT02963766) of 154 young people with a mean age of 14.5 years, which found Trulicity superior to placebo on HbA1c. The cardiovascular indication applies to adults only.